Fennec Pharmaceuticals (FENC) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Surrozen (SRZN) has outperformed Fennec Pharmaceuticals (FENC) over the past year, gaining 99.2% versus a gain of 15.3%. Over five years, FENC leads with a +15.7% price change compared with -70.5% for SRZN. Fennec Pharmaceuticals is the larger company by market cap ($378.7 million vs $355.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FENC | SRZN |
|---|---|---|
| Share price | $10.80 | $30.28 |
| Market cap | $378.73M | $355.90M |
| 1-day change | +1.60% | +8.26% |
| YTD return | +38.05% | +23.76% |
| 1-year return | +15.29% | +99.22% |
| 5-year return | +15.67% | -70.50% |
| Forward P/E | 11.39 | — |
| EPS (TTM) | $-0.12 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.25 | $37.83 |
| 52-week low | $5.65 | $11.39 |
| Distance from 52-week high | -18.49% | -19.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +63.61% | +59.84% |
| Average volume | 193.13K | 483.28K |
| Shares outstanding | 35.07M | 11.75M |
| Employees | 35 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed FENC by 83.9 percentage points over the past year.
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
FENC vs SRZN FAQ
Which is bigger, Fennec Pharmaceuticals or Surrozen?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $378.73M compared with $355.90M for Surrozen (SRZN).
Which stock has performed better over the past year, FENC or SRZN?
SRZN returned +99.22% over the past 12 months, compared with +15.29% for FENC (price return, excluding dividends). Past performance does not predict future results.
Are Fennec Pharmaceuticals and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.